GlassScriptPhysician profile
Syed Hasan
NPI 1649596818
$4,964.29
in general payments reported to CMS, 2019-2025
30 companies · $1,311 in 2025
The $1,311 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.00 · 2021: $455 · 2022: $760 · 2023: $1,153 · 2024: $1,265 · 2025: $1,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,710 · Education: $18.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,710.35 |
| Education | $18.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,600.80 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $772.51 | 2021-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $404.55 | 2021-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $281.69 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $251.09 | 2024-2025 | Zenpep, Vowst |
| Pfizer INC. | $152.73 | 2022-2025 | |
| Madrigal Pharmaceuticals | $148.41 | 2024-2025 | Rezdiffra |
| Janssen Scientific Affairs, LLC | $125.00 | 2021 | |
| Nestle Healthcare Nutrition INC. | $122.97 | 2022-2023 | |
| Janssen Biotech, INC. | $115.84 | 2021-2025 | Tremfya, Stelara |
| Boston Scientific Corporation | $112.28 | 2021 | |
| Merck Sharp & Dohme LLC | $109.42 | 2022-2024 | Dificid |
| Gilead Sciences, INC. | $98.06 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $82.45 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $80.68 | 2023-2025 | Rebyota |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $70.67 | 2022-2023 | Zeposia |
| Ardelyx, INC. | $65.69 | 2024-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $51.28 | 2024-2025 | Iqirvo |
| Braintree Laboratories, INC. | $46.78 | 2022-2024 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $41.57 | 2024 | |
| Celltrion USA INC. | $39.14 | 2024 | Zymfentra |
| Qol Medical, LLC | $34.35 | 2023 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $29.75 | 2023-2024 | Dupixent |
| Biogen, INC. | $24.24 | 2025 | Vumerity |
| Ucb, INC. | $20.00 | 2019 | |
| Lilly USA, LLC | $18.67 | 2024 | Omvoh |
| Novo Nordisk INC | $17.20 | 2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $16.13 | 2021 | |
| Sight Sciences, INC. | $15.33 | 2025 | Omni Surgical System |
| Organon LLC | $15.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Hasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.